Investments overview
186 investments
| Title Sort descending | Period | Programme | |
|---|---|---|---|
| 4-in-1 | 2019 - 2021 | International collaborations
|
|
|
4-in-1
Period
2019 - 2021
Region
Program
Internationalt samarbejde Area
Biotek, Medico og Sundhed Investment
Percentage
43.98 Invested
3.8 mill. Budget
8.5 mill. Partners
MotilityCount ApS, Ansager Hestehospital ApS, IVI VALENCIA S.L. People
MotilityCount ApS
Read more about the project
| |||
| A coherent approach to virtual assessments of structural robustness | 2019 - 2022 | Industrial Researcher
|
|
|
A coherent approach to virtual assessments of structural robustness
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
54.86 Invested
1.1 mill. Budget
2.0 mill. Partners
Technical University of Denmark, Novo Nordisk A/S People
Novo Nordisk A/S
Read more about the project
| |||
| A molecular display platform for screening and direct selection of functionally active peptides | 2019 - 2021 | Industrial Researcher
|
|
|
A molecular display platform for screening and direct selection of functionally active peptides
Period
2019 - 2021
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
45.61 Invested
828.000 Budget
1.8 mill. Partners
Danmarks Tekniske Universitet, ZEALAND PHARMA A/S People
ZEALAND PHARMA A/S
Read more about the project
| |||
| A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals | 2019 - 2022 | Industrial Researcher
|
|
|
A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
47.06 Invested
1.1 mill. Budget
2.3 mill. Partners
University of Copenhagen, Fida Biosystems ApS People
Fida Biosystems ApS
Read more about the project
| |||
| A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation | 2019 - 2020 | Innofounder
|
|
|
A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation
Period
2019 - 2020
Region
Region Hovedstaden Program
Innofounder Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
460.000 Budget
460.000 Partners
GO-PEN ApS People
GO-PEN ApS
Read more about the project
| |||
| Accelerating vaccine development through a deep learning and probabilistic programming approach to protein structure prediction | 2019 - 2022 | Industrial Researcher
|
|
|
Accelerating vaccine development through a deep learning and probabilistic programming approach to protein structure prediction
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
42.6 Invested
1.1 mill. Budget
2.5 mill. Partners
University of Copenhagen, EVAXION BIOTECH A/S People
EVAXION BIOTECH A/S
Read more about the project
| |||
| ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars | 2019 - 2020 | Innobooster
|
|
|
ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars
Period
2019 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
490.050 Budget
1.5 mill. Partners
AirClean Denmark ApS People
ACD ApS
Read more about the project
| |||
| ACOUPLAST | 2019 - 2022 | International collaborations
|
|
|
ACOUPLAST
Period
2019 - 2022
Region
Program
Internationalt samarbejde Area
Biotek, Medico og Sundhed Investment
Percentage
24.2 Invested
2.8 mill. Budget
11.5 mill. Partners
DTU, Ortofon A/S, AcouSort AB, Lund University People
DTU
Read more about the project
| |||
| ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs) | 2019 - 2020 | Innobooster
|
|
|
ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs)
Period
2019 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
30 Invested
483.600 Budget
1.6 mill. Partners
ADCendo ApS People
ADCendo ApS
Read more about the project
| |||
| ADCendo ApS - first-in-class targeted cancer drugs | 2019 - 2020 | Innofounder
|
|
|
ADCendo ApS - first-in-class targeted cancer drugs
Period
2019 - 2020
Region
Region Hovedstaden Program
Innofounder Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
460.000 Budget
460.000 Partners
ADCendo ApS People
ADCendo ApS
Read more about the project
| |||
| Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D | 2019 - 2024 | Grand Solutions
|
|
|
Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D
Period
2019 - 2024
Region
Region Hovedstaden Program
Grand Solutions Area
Biotek, Medico og Sundhed Investment
Percentage
52.12 Invested
17.1 mill. Budget
32.9 mill. Partners
Novo Nordisk A/S, Aalborg Universitetshospital, Region Sjælland, Aalborg University, Technical University of Denmark, University of Cambridge, Glooko AB People
NOVO NORDISK A/S
Read more about the project
| |||
| Advanced characterization of large scale fermentations | 2019 - 2021 | Industrial Researcher
|
|
|
Advanced characterization of large scale fermentations
Period
2019 - 2021
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
46.94 Invested
828.000 Budget
1.8 mill. Partners
Technical University of Denmark, FreeSense ApS People
FreeSense ApS
Read more about the project
| |||
| Advanced modelling for prediction and control of related substances in an antibiotic fermentation processes | 2019 - 2022 | Industrial Researcher
|
|
|
Advanced modelling for prediction and control of related substances in an antibiotic fermentation processes
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
47.73 Invested
1.1 mill. Budget
2.2 mill. Partners
Technical University of Denmark, LEO PHARMA A/S People
LEO PHARMA A/S
Read more about the project
| |||
| Advancing biological solutions for biofouling | 2019 - 2022 | Industrial Researcher
|
|
|
Advancing biological solutions for biofouling
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
56.02 Invested
1.1 mill. Budget
1.9 mill. Partners
Aarhus University, Novozymes A/S People
Novozymes A/S
Read more about the project
| |||
| Advancing KP405 - A Novel, First-in-Class, Disease Modifying Treatment for Parkinson's Disease | 2019 - 2020 | Innobooster
|
|
|
Advancing KP405 - A Novel, First-in-Class, Disease Modifying Treatment for Parkinson's Disease
Period
2019 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
4.0 mill. Budget
12.0 mill. Partners
Kariya Pharmaecuticals IVS People
Kariya Pharmaceuticals ApS
Read more about the project
| |||